MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Dasatanib: CML drug evokes faster response

Back to cancer blog Blogs list Cancer blog  


Subscribe To Cancer Blog RSS Feed  RSS content feed What is RSS feed?

Dasatanib: CML drug evokes faster response




Dasatanib, a medicine currently approved as therapy for drug-resistant chronic myeloid leukemia (CML), provided patients with quicker, better responses as a first treatment than the existing front-line drug, as per scientists at The University of Texas MD Anderson Cancer Center.

The findings were presented at the 46th Annual Meeting of the American Society of Clinical Oncology today, and reported in the New England Journal (NEJM) Hagop Kantarjian, M.D., professor and chair of MD Anderson's Department of Leukemia, presented the findings and is the corresponding author on the published study.



Dasatanib: CML drug evokes faster response

Currently, imatinib, or Gleevec , is the approved initial treatment for CML, which has increased the five-year survival rate for the disease from 50 percent to 90 percent, said Kantarjian. However, 30-40 percent of imatinib patients do not achieve confirmed cytogenic complete response (CCyR), or the absence of the defective chromosome that causes the disease, within a year. This benchmark is clearly linked to improvements in long-term outcome, said Kantarjian.

"Prior research conducted at MD Anderson observed that more patients taking dasatinib were achieving complete responses more quickly than they do on the current standard of care," said Kantarjian. "In this pivotal Phase III study, we confirmed that dasatinib gets more patients to high-quality remission faster than imatinib, making it a superior front-line treatment. Dasatinib, on average, also has a more favorable side-effect profile".

For the multinational Phase III study, known as DASSIN (Dasatinib versus Imatinib Study In therapy-nave CML patients), 519 newly diagnosed CML patients who had received no previous therapy were randomized to receive either dasatinib, also known as Sprycel , 100 milligrams once daily (259 patients), or imatinib, 400 milligrams once daily (260 patients). CCyR, confirmed on two evaluations, was the study's primary endpoint. Secondary endpoints included rate of and times to CCyR and major molecular response (MMR), defined as a level of.1 percent or lower of the defective chromosome, as well as safety.

After a minimum follow-up of 12 months, the scientists observed that the rates of confirmed CCyR and MMR in those taking dasatinib were 77 percent and 46 percent, respectively, in comparison to 66 percent and 28 percent, on the imatinib arm.

Therapy failed in nine patients (3.5 percent) in those taking imatinib, in comparison to five patients (1.9 percent) taking dasatanib. The dasatanib arm reported fewer side effects - nausea, vomiting, muscle inflammation, rash, fluid retention - with most other toxicities being similar in both arms.

"We've learned that in cancer treatment, it's important to use your big guns up front. We know that achieving complete cytogenetic response within a year of starting therapy is linked to more favorable long-term survival; therefore, using this second-generation drug first will likely improve outcomes for patients with chronic myeloid leukemia," said Kantarjian.

CML is caused by an abnormality known as the Philadelphia chromosome that produces an aberrant protein, Bcr-Abl, which causes the overproduction of one type of white blood cell that drives the disease. Dasatinib, a tyrosine kinase inhibitor, blocks the action of Bcr-Abl; the drug is currently approved by the U.S. Food and Drug Administration for patients who can't tolerate imatinib or whose CML resists the drug.


Posted by: Janet    Source




Did you know?
Dasatanib, a medicine currently approved as therapy for drug-resistant chronic myeloid leukemia (CML), provided patients with quicker, better responses as a first treatment than the existing front-line drug, as per scientists at The University of Texas MD Anderson Cancer Center.

Medicineworld.org: Dasatanib: CML drug evokes faster response

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.